SC 13D 1 babylon_sch13d.htm BABYLON SCHEDULE 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	SCHEDULE 13D

	UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. __)*

Babylon Holdings Limited

(Name of Issuer)

Class A ordinary shares, par value $0.0000422573245084686
(Title of Class of Securities)

G07031100
(CUSIP Number)

Anders F. Börjesson
c/o VNV (Cyprus) Limited
1, Lampousas Street, 1095 Nicosia, Cyprus
+46 8 545 015 50
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

November 3, 2022
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d‑l(e), 240.13d‑l(f) or 240.13d‑1(g), check the following box. ☐

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 15

CUSIP No. G07031100

1	NAMES OF REPORTING PERSONS VNV (Cyprus) Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable
6	CITIZENSHIP OR PLACE OF ORGANIZATION Cyprus
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			7	SOLE VOTING POWER 83,120,478⁽¹⁾
			8	SHARED VOTING POWER 0
			9	SOLE DISPOSITIVE POWER 83,120,478⁽¹⁾
			10	SHARED DISPOSITIVE POWER 0
11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 83,120,478⁽¹⁾
12		CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13.4%⁽²⁾
14		TYPE OF REPORTING PERSON CO

(1)	Reflects 83,120,478 Class A ordinary shares par value $0.0000422573245084686 (the “Class A Shares”) of the Issuer held by VNV (Cyprus) Limited (“VNV Cyprus”), a wholly-owned subsidiary of VNV Global AB (publ) (“VNV Global”), a Swedish publicly traded company.

(2)

The percentage calculated is based on 619,979,342 Class A Shares outstanding as of November 3, 2022 as reported in the Form 6-K filed by the Issuer on November 4, 2022, which includes (i) 189,924,499 Class A Shares issued in a private placement pursuant to the 2022 PIPE Subscription Agreements (defined below) reported in the Form 6-K filed by the Issuer on November 4, 2022 and (ii) 79,637,576 Class A Shares that were converted into Class A Shares from the total outstanding Class B ordinary shares in accordance with Article 8(a) of the Issuer’s Amended and Restated Memorandum and Articles of Association dated October 21, 2021 (the “Articles”) reported in the Form 6-K filed by the Issuer on November 4, 2022.

Page 3 of 15

CUSIP No. G07031100

1		NAMES OF REPORTING PERSONS Global Health Equity (Cyprus) Ltd
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS OO
5		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable
6		CITIZENSHIP OR PLACE OF ORGANIZATION Cyprus
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			7	SOLE VOTING POWER 17,745,304⁽¹⁾
				8	SHARED VOTING POWER 0
				9	SOLE DISPOSITIVE POWER 17,745,304⁽²⁾
				10	SHARED DISPOSITIVE POWER 0
11			AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 17,745,304⁽¹⁾
12			CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
13			PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.9%⁽¹⁾⁽³⁾
14			TYPE OF REPORTING PERSON CO

(1)

Global Health Equity (Cyprus) Ltd (“Global Health Equity”) is the holder of 17,745,304 Class A Shares. VNV Global indirectly holds, through its direct wholly-owned subsidiary, VNV Sweden AB (“VNV Sweden”), approximately 37.35% of the shares in Global Health Equity AB (publ) (“Global Health (publ)”), the direct and sole shareholder of Global Health Equity, with the remainder held by other foreign institutional investors and individuals. VNV Global is the direct and sole shareholder of VNV Sweden. Investment decisions relating to holdings of VNV Sweden are made by a board of directors consisting of three individuals on the basis of recommendations issued by a five-member board of directors of VNV Global. Investment decisions relating to holdings of Global Health Equity are taken by a board of directors that consists of P.C. Nordic Administration Limited, a third-party corporate services provider, taking into account recommendations issued by a three-member board of directors of Global Health (publ). The Global Health (publ) board is currently comprised of three members, constituting all managing members of VNV Global.

(2)

The percentage calculated is based on 619,979,342 Class A Shares outstanding as of November 3, 2022 as reported in the Form 6-K filed by the Issuer on November 4, 2022, which includes (i) 189,924,499 Class A Shares issued in a private placement pursuant to the 2022 PIPE Subscription Agreements (defined below) reported in the Form 6-K filed by the Issuer on November 4, 2022 and (ii) 79,637,576 Class A Shares that were converted into Class A Shares from the total outstanding Class B ordinary shares in accordance with Article 8(a) of the Issuer’s Articles reported in the Form 6-K filed by the Issuer on November 4, 2022.

Page 4 of 15

CUSIP No. G07031100

1		NAMES OF REPORTING PERSONS VNV Sweden AB
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3		SEC USE ONLY
4		SOURCE OF FUNDS OO
5		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable
6		CITIZENSHIP OR PLACE OF ORGANIZATION Sweden
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			7	SOLE VOTING POWER 0
				8	SHARED VOTING POWER 17,745,304⁽¹⁾
				9	SOLE DISPOSITIVE POWER 0
				10	SHARED DISPOSITIVE POWER 6,627,871⁽²⁾
11			AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 17,745,304⁽¹⁾
12			CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
13			PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.9%⁽²⁾
14			TYPE OF REPORTING PERSON CO

(1)

Global Health Equity is the holder of 17,745,304 Class A Shares. VNV Global indirectly holds, through its direct wholly-owned subsidiary, VNV Sweden, approximately 37.35% of the shares in Global Health (publ), the direct and sole shareholder of Global Health Equity, with the remainder held by other foreign institutional investors and individuals. VNV Global is the direct and sole shareholder of VNV Sweden. Investment decisions relating to holdings of VNV Sweden are made by a board of directors consisting of three individuals on the basis of recommendations issued by a five-member board of directors of VNV Global. Investment decisions relating to holdings of Global Health Equity are taken by a board of directors that consists of P.C. Nordic Administration Limited, a third-party corporate services provider, taking into account recommendations issued by a three-member board of directors of Global Health (publ). The Global Health (publ) board is currently comprised of three members, constituting all managing members of VNV Global.

(2)

The percentage calculated is based on 619,979,342 Class A Shares outstanding as of November 3, 2022 as reported in the Form 6-K filed by the Issuer on November 4, 2022, which includes (i) 189,924,499 Class A Shares issued in a private placement pursuant to the 2022 PIPE Subscription Agreements (defined below) reported in the Form 6-K filed by the Issuer on November 4, 2022 and (ii) 79,637,576 Class A Shares that were converted into Class A Shares from the total outstanding Class B ordinary shares in accordance with Article 8(a) of the Issuer’s Articles reported in the Form 6-K filed by the Issuer on November 4, 2022.

Page 5 of 15

CUSIP No. G07031100

1	NAMES OF REPORTING PERSONS VNV Global AB (publ)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable
6	CITIZENSHIP OR PLACE OF ORGANIZATION Sweden
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:			7	SOLE VOTING POWER 0
			8	SHARED VOTING POWER 100,865,782⁽¹⁾
			9	SOLE DISPOSITIVE POWER 0
			10	SHARED DISPOSITIVE POWER 89,748,955⁽²⁾
11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 100,865,782⁽¹⁾
12		CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 16.3%⁽³⁾
14		TYPE OF REPORTING PERSON CO

(1)	Reflects (i) 83,120,478 Class A Shares held by VNV Cyprus and (ii) 17,745,304 Class A Shares held by Global Health Equity.

(2)	Reflects (i) 83,120,478 Class A Shares held by VNV Cyprus and (ii) 6,627,871 Class A Shares held by Global Health Equity.

(3)

The percentage calculated is based on 619,979,342 Class A Shares outstanding as of November 3, 2022 as reported in the Form 6-K filed by the Issuer on November 4, 2022, which includes (i) 189,924,499 Class A Shares issued in a private placement pursuant to the 2022 PIPE Subscription Agreements (defined below) reported in the Form 6-K filed by the Issuer on November 4, 2022 and (ii) 79,637,576 Class A Shares that were converted into Class A Shares from the total outstanding Class B ordinary shares in accordance with Article 8(a) of the Issuer’s Articles reported in the Form 6-K filed by the Issuer on November 4, 2022.

SCHEDULE 13D

Item 1. Security and Issuer

This statement on Schedule 13D (this “Schedule 13D”) relates to the Class A Shares of Babylon Holdings Ltd. (the “Issuer”), whose principal executive offices are located at 1 Knightsbridge Green, London, SW1X 7QA, United Kingdom.

Item 2. Identity and Background

(a) This Schedule 13D is being filed by the following persons (each a “Reporting Person” and, collectively, the “Reporting Persons”):

i.	VNV (Cyprus) Limited (“VNV Cyprus”);

ii.	Global Health Equity (“Cyprus) Ltd (Global Health Equity”);

iii.	VNV Sweden AB (“VNV Sweden”); and

iv.	VNV Global AB (publ) (“VNV Global”).

(b) The principal business address of the Reporting Persons is as follows:

i.	VNV Cyprus: 1, Lampousas Street, 1095 Nicosia, Cyprus;

ii.	Global Health Equity: Stasikratous, 22, Olga Court, Office 104, 1065 Nicosia, Cyprus;

iii.	VNV Sweden: Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden; and

iv.	VNV Global: Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden.

(c) VNV Global is an investment company whose common shares are listed on Nasdaq Stockholm, Mid Cap segment, with the ticker VNV. VNV Cyprus is a wholly-owned subsidiary of VNV Global and its principal business is asset holding and management. VNV Sweden is a wholly-owned subsidiary of VNV Global and its principal business is asset holding and management. Global Health Equity is a wholly-owned subsidiary of Global Health (publ) and its principal business is asset holding and management. VNV Global indirectly holds, through its direct wholly-owned subsidiary, VNV Sweden, approximately 37.35% of the shares in Global Health (publ), with the remainder held by other foreign institutional investors and individuals.

The name, business address, present principal occupation or employment and citizenship of each director and executive officer of the Reporting Persons are set forth on Schedule I hereto and incorporated herein by reference.

(d) During the last five years, the Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person were not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

(f) VNV Cyprus is organized under the laws of Cyprus, Global Health Equity is organized under the laws of Cyprus, VNV Sweden is organized under the laws of Sweden and VNV Global is organized under the laws of Sweden.

Item 3. Source and Amount of Funds or Other Consideration

The information in Item 4 below is incorporated by reference in this Item 3. As described in Item 4, the securities reported on this Schedule 13D reflect the issuance of the 2022 PIPE Shares (as defined below).

Item 4. Purpose of the Transaction

Subscription Agreement

On or around October 16, 2022, the Issuer entered into subscription agreements (the “2022 PIPE Subscription Agreements”), pursuant to which the Issuer agreed to issue and sell to certain subscribers (the “Subscribers”) in a private placement an aggregate of 189,924,499 Class A Shares (the “2022 PIPE Shares”), at a price of $0.42122 per share (the “2022 Private Placement”). VNV Cyprus purchased 46,531,503 Class A Shares in the 2022 Private Placement, for total consideration of $19,600,000.00. The 2022 Private Placement closed on November 3, 2022 (the “Closing Date”). VNV Cyprus used proceeds from investments to fund its investment in the 2022 Private Placement.

As a condition to closing the 2022 Private Placement, ALP Partners Limited (“ALP Partners”), furnished an undertaking, referred to as the “Approval of Conversion” to deliver to the Issuer and the Issuer’s transfer agent a letter instructing the total outstanding Class B ordinary shares be converted into 79,637,576 Class A Shares in accordance with Article 8(a) of the Issuer’s Articles, and in connection therewith, that the transfer agent re-designate such Class B ordinary shares, and in exchange, issue to ALP Partners, from the Issuer’s established conversion reserve account, the 79,637,576 Class A Shares, in book-entry form.

According to the press release included as Exhibit 99.1 to the Form 6-K filed on October 18, 2022, the Issuer expects to use the proceeds from the 2022 Private Placement to fund the ongoing development of its digital-first platform and services for managing population health, working capital and other general corporate purposes.

The foregoing description of the 2022 PIPE Subscription Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the 2022 PIPE Subscription Agreements, a copy which is attached as Exhibit 99.3 to this Schedule 13D and is incorporated herein by reference.

Registration Rights

On October 21, 2021, the Issuer became a public reporting company following the consummation of the transactions contemplated by that certain Merger Agreement, dated June 3, 2021, with Alkuri Global Acquisition Corp., a publicly traded special purpose acquisition company (the “SPAC”), whereby the Issuer’s shareholders’ shares were exchanged for shares in the SPAC and the shares of the Issuer began trading on the New York Stock Exchange (the “De-SPAC Transaction”).

In connection with the De-SPAC Transaction, the Issuer, VNV Cyprus and certain other investors entered into a registration rights agreement dated as of June 3, 2021 (the “Registration Rights Agreement”), with respect to certain shares held by the investors, including Class A Shares (the “2021 PIPE Shares”) acquired pursuant to the subscription agreements, dated as of June 3, 2021, entered into, by and among the Issuer, the SPAC and certain subscribers, whereby VNV Cyprus acquired 500,000 2021 PIPE Shares at a price of $10.00 per share. The registration rights pursuant to the Registration Rights Agreement, include certain piggyback registration rights and customary demand registration rights.

Pursuant to the 2022 PIPE Subscription Agreements, the Subscribers are entitled to registration rights for their 2022 PIPE Shares under the Registration Rights Agreement and the Issuer agreed to file a registration statement for a shelf registration covering the 2022 PIPE Shares within 20 days of the Closing Date, to use commercially reasonable efforts to have the registration statement be declared effective as soon as practicable thereafter and to file amendments as necessary.

The foregoing description of the Registration Rights Agreement and any other registration rights under the 2022 PIPE Subscription Agreements, does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement and the 2022 PIPE Subscription Agreements, copies of which are attached as Exhibits 99.2 and 99.3 to this Schedule 13D and are incorporated herein by reference.

General

The Reporting Persons and their respective representatives have engaged and/or may engage, from time to time, in discussions with the Issuer’s management and/or board of directors (the “Board”), including any special committees of the Board, and/or their respective advisors, regarding, among other things, the Issuer’s business, strategies, management, governance, operations, personnel, performance, financial matters, capital structure, corporate expenses, status of projects, hedging, environmental, health and safety matters and strategic and other transactions (including transactions involving one or more of the Reporting Persons and/or their respective affiliates and/or portfolio companies and/or other stockholders or creditors of the Issuer), and have engaged and/or intend to, from time to time, engage in discussions with other current or prospective holders of Class A Shares and/or other equity, debt, notes, instruments or securities, or rights convertible into or exchangeable or exercisable for Class A Shares or such other equity, debt, notes, instruments or securities, of the Issuer (collectively, “Securities”), industry analysts, research analysts, rating agencies, existing or potential strategic partners of the Issuer, acquirers or competitors, financial sponsors, investment firms, investment professionals, capital and potential capital sources (including co-investors), operators, financial, and other consultants and advisors and other third parties regarding such matters (in each case, including with respect to providing or potentially providing capital to the Issuer or to existing or potential strategic partners or acquirers of the Issuer) as well as other matters set forth in clauses (a)-(j) of Item 4 of Schedule 13D. These discussions have encompassed, and/or the Reporting Persons expect will encompass, a broad range of matters relating to the Issuer , including, among other things, the Issuer’s business, operations, finances, management, organizational documents, ownership, capital and corporate structure, dividend policy, corporate governance, the Board and committees thereof, management and director incentive programs, strategic alternatives and transactions, including the sale of the Issuer, its Securities or one or more of its subsidiaries or their respective businesses or assets or a business combination or other strategic transaction involving the Issuer or one or more of its subsidiaries, and any regulatory or legal filings, clearances, approvals or waivers relating to the foregoing. The Reporting Persons may exchange information with the Issuer or other persons or entities pursuant to confidentiality or similar agreements and may enter into expense reimbursement agreements with the Issuer and others.

The Reporting Persons intend to review their investment in the Issuer on an ongoing basis. Depending on various factors, including the outcome of any discussions referenced above, the Issuer’s business, financial position, results, strategic direction or prospects or any strategic alternatives or transactions, actions taken by the Issuer’s management or the Board, price levels of one or more Securities, other investment opportunities available to the Reporting Persons, the available capital of the Reporting Persons, the respective portfolio management considerations (including investment horizons) of the Reporting Persons, conditions in the securities, loan or bond markets, factors relating to COVID-19 and other potential pandemics, general economic or industry conditions or any changes in law or regulations, the Reporting Persons expect that they will seek to dispose, or cause to be disposed (including, without limitation, distributing some or all of the shares of Class A Shares to certain of the Reporting Persons’ respective members, partners, stockholders and/or beneficiaries, as applicable), some or all of the shares of Class A Shares beneficially owned by them, in the public market, in privately negotiated transactions or otherwise, pledging their interest in their shares of Class A Shares as a means of obtaining liquidity or as credit support for loans or other extensions of credit, or entering into derivatives transactions and other agreements or instruments that decrease the Reporting Persons’ economic exposure with respect to their investment in the Issuer.

Certain plans or proposals may from time to time be discussed or considered by the directors of the Issuer, including Per Brilioth, who is both a member of the board of directors of the Issuer and a managing director of VNV Global.

Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

The information set forth or incorporated by reference in Items 2 and 4 of this Schedule 13D is incorporated by reference in this Item 5.

(a)—(b) Based on 619,979,342 Class A Shares outstanding as of November 3, 2022 as reported in the Form 6-K filed by the Issuer on November 4, 2022, which includes (i) 189,924,499 Class A Shares issued in a private placement pursuant to the 2022 PIPE Subscription Agreements (defined below) reported in the Form 6-K filed by the Issuer on November 4, 2022 and (ii) 79,637,576 Class A Shares that were converted into Class A Shares from the total outstanding Class B ordinary shares in accordance with Article 8(a) of the Issuer’s Articles reported in the Form 6-K filed by the Issuer on November 4, 2022.

Reporting Person	Amount beneficially owned	Percent of class	Sole power to vote or to direct the vote	Shared power to vote or to direct the vote	Sole power to dispose or to direct the disposition	Shared power to dispose or to direct the disposition
VNV Cyprus	83,120,478	13.4%	83,120,478	0	83,120,478	0
VNV Global	100,865,782	16.3%	0	100,865,782	0	89,748,955
Global Health Equity	17,745,304	2.9%	17,745,304	0	17,745,304	0
VNV Sweden	17,745,304	2.9%	0	17,745,304	0	6,627,871

Except as set forth above, neither the Reporting Persons nor, to the knowledge of the Reporting Persons, any of the persons named in Schedule I hereto, beneficially own any Class A Shares.

(c) Except as described in this Schedule 13D, neither the Reporting Persons, nor, to the knowledge of the Reporting Persons, any of the persons set forth on Schedule I hereto, have effected any transactions in the Class A Shares in the past 60 days.

(d)—(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information in Item 4 is incorporated herein by reference. Other than the agreements described in Item 4, as of the date hereof, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer.

Item 7. Material to be Filed as Exhibits.

EXHIBIT NO.	NAME

99.1		Merger Agreement, dated as of June 3, 2021, by and among Alkuri Global Acquisition Corp., Babylon Holdings Limited, Liberty USA Merger Sub, Inc., Alkuri Sponsors LLC, and Dr. Ali Parsadoust (incorporated by reference to Exhibit 2.1 of Alkuri Global Acquisition Corp.’s Form F-4, filed with the SEC on July 2, 2022)
99.2		Registration Rights Agreement dated as of June 3, 2021, by and among Alkuri Sponsors LLC, Babylon Holdings Limited and certain shareholders of Babylon Holdings Limited (incorporated by reference to Exhibit 10.6 of Alkuri Global Acquisition Corp.’s Form 8-K, filed with the SEC on June 4, 2021)
99.3		Form of Initial Subscription Agreement, dated on or about October 16, 2022 (incorporated by reference to Exhibit 10.1 of Babylon Holdings Limited’s Form 6-K, filed with the SEC on October 18, 2022)

99.4		Joint Filing Agreement, dated as of November 10, 2022, by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

Date: November 10, 2022

VNV (CYPRUS) LIMITED

By: /s/ Boris Sinegubko

Name: Boris Sinegubko

Title: Managing Director

GLOBAL HEALTH EQUITY (CYPRUS) LTD

By: P.C. Nordic Administration Limited

By: /s/ Maria Zembyla

Name: Maria Zembyla, on behalf of P.C. Nordic Administration Limited

Title: Director

VNV SWEDEN AB

By: /s/ Per Brilioth

Name: Per Brilioth

Title: Managing Director

VNV GLOBAL AB (PUBL)

By: /s/ Per Brilioth

Name: Per Brilioth

Title: Managing Director

SCHEDULE I

Directors and Executive Officers of the Reporting Persons

The following table sets forth certain information with respect to the directors and executive officers of the Reporting Persons. The business address of each director and executive officer of VNV (Cyprus) Limited is c/o 1, Lampousas Street, 1095 Nicosia, Cyprus. The business address of each director and executive officer of Global Health Equity (Cyprus) Ltd is c/o Stasikratous, 22, Olga Court, Office 104, 1065 Nicosia, Cyprus. The business address of each director and executive officer of VNV Sweden AB is c/o Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden. The business address of each director and executive officer of VNV Global AB (publ) is c/o Mäster Samuelsgatan 1, 111 44 Stockholm, Sweden.

VNV (CYPRUS) LIMITED

Directors

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
ELENI CHRYSOSTOMIDES (CYPRUS)	DIRECTOR
GEORGIA CHRYSOSTOMIDES (CYPRUS)	DIRECTOR
CHRYSTALLA DEKATRIS (CYPRUS)	DIRECTOR
BORIS SINEGUBKO (CYPRUS)	DIRECTOR

Executive Officers

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
N/A	N/A

GLOBAL HEALTH EQUITY (CYPRUS) LTD

Directors

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
P.C. NORDIC ADMINISTRATION LIMITED (CYPRUS)	PROFESSIONAL SERVICE PROVIDER

Executive Officers

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
N/A	N/A

VNV SWEDEN AB

Directors

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
PER BRILIOTH (SWEDEN)	DIRECTOR
NADJA BORISOVA (SWEDEN)	DIRECTOR
ANDERS F. BÖRJESSON (SWEDEN)	DIRECTOR

Executive Officers

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
PER BRILIOTH (SWEDEN)	MANAGING DIRECTOR OF VNV GLOBAL AB (PUBL)

VNV GLOBAL AB (PUBL)

Directors

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
LARS O GRÖNSTEDT (SWEDEN)	DIRECTOR
JOSH BLACHMAN (USA)	DIRECTOR
PER BRILIOTH (SWEDEN)	DIRECTOR
YLVA LINDQUIST (SWEDEN)	DIRECTOR
KEITH RICHMAN (USA)	DIRECTOR

Executive Officers

NAME (CITIZENSHIP)	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
PER BRILIOTH	MANAGING DIRECTOR OF VNV GLOBAL AB (PUBL)
NADJA BORISOVA	CHIEF FINANCIAL OFFICER OF VNV GLOBAL AB (PUBL)
ANDERS F. BÖRJESSON	GENERAL COUNSEL OF VNV GLOBAL AB (PUBL)
BJÖRN VON SIVERS	INVESTMENT MANAGER AND HEAD OF INVESTOR RELATIONS OF VNV GLOBAL AB (PUBL)

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the Class A Shares of Babylon Holdings Limited. The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate. This joint filing agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.

VNV (CYPRUS) LIMITED

By: /s/ Boris Sinegubko

Name: Boris Sinegubko

Title: Managing Director

GLOBAL HEALTH EQUITY (CYPRUS) LTD

By: P.C. Nordic Administration Limited

By: /s/ Maria Zembyla

Name: Maria Zembyla, on behalf of P.C. Nordic Administration Limited

Title: Director

VNV SWEDEN AB

By: /s/ Per Brilioth

Name: Per Brilioth

Title: Managing Director

VNV GLOBAL AB (PUBL)

By: /s/ Per Brilioth

Name: Per Brilioth

Title: Managing Director

SEC Form SC 13D filed by Babylon Holdings Limited